Cytoplasmic TRADD confers a worse prognosis in glioblastoma.
Journal: 2014/March - Neoplasia
ISSN: 1476-5586
PUBMED: 23908590
Abstract:
Tumor necrosis factor receptor 1 (TNFR1)-associated death domain protein (TRADD) is an important adaptor in TNFR1 signaling and has an essential role in nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) activation and survival signaling. Increased expression of TRADD is sufficient to activate NF-κB. Recent studies have highlighted the importance of NF-κB activation as a key pathogenic mechanism in glioblastoma multiforme (GBM), the most common primary malignant brain tumor in adults.We examined the expression of TRADD by immunohistochemistry (IHC) and find that TRADD is commonly expressed at high levels in GBM and is detected in both cytoplasmic and nuclear distribution. Cytoplasmic IHC TRADD scoring is significantly associated with worse progression-free survival (PFS) both in univariate and multivariate analysis but is not associated with overall survival (n = 43 GBMs). PFS is a marker for responsiveness to treatment. We propose that TRADD-mediated NF-κB activation confers chemoresistance and thus a worse PFS in GBM. Consistent with the effect on PFS, silencing TRADD in glioma cells results in decreased NF-κB activity, decreased proliferation of cells, and increased sensitivity to temozolomide. TRADD expression is common in glioma-initiating cells. Importantly, silencing TRADD in GBM-initiating stem cell cultures results in decreased viability of stem cells, suggesting that TRADD may be required for maintenance of GBM stem cell populations. Thus, our study suggests that increased expression of cytoplasmic TRADD is both an important biomarker and a key driver of NF-κB activation in GBM and supports an oncogenic role for TRADD in GBM.
Relations:
Content
Citations
(8)
References
(47)
Diseases
(2)
Drugs
(2)
Chemicals
(3)
Genes
(2)
Organisms
(1)
Processes
(3)
Anatomy
(3)
Affiliates
(1)
Similar articles
Articles by the same authors
Discussion board
Neoplasia 15(8): 888-897

Cytoplasmic TRADD Confers a Worse Prognosis in Glioblastoma<sup><a href="#FN1" rid="FN1" class=" fn">1</a>,</sup><sup><a href="#FN2" rid="FN2" class=" fn">2</a></sup>

+2 authors
Supplementary Figures and Tables:
Click here to view.(31K, pdf)
Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, TX
Department of Biostatistics, University of Texas Southwestern Medical Center, Dallas, TX
Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX
Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX
Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX
Department of Molecular Physiology and Pharmacology, Tufts University School of Medicine, Boston, MA
Department of Neurosurgery, Tufts University School of Medicine, Boston, MA
VA North Texas Health Care System, Dallas, TX
Address all correspondence to: Amyn A. Habib, MD, University of Texas Southwestern Medical Center, North Texas VA Healthcare System, Mail Code 151, 4500 South Lancaster Road, Dallas, TX 75216. E-mail: ude.nretsewhtuoSTU@bibaH.nymA
Address all correspondence to: Amyn A. Habib, MD, University of Texas Southwestern Medical Center, North Texas VA Healthcare System, Mail Code 151, 4500 South Lancaster Road, Dallas, TX 75216. E-mail: ude.nretsewhtuoSTU@bibaH.nymA
Received 2013 Mar 5; Revised 2013 Apr 26; Accepted 2013 Apr 29.

Abstract

Tumor necrosis factor receptor 1 (TNFR1)-associated death domain protein (TRADD) is an important adaptor in TNFR1 signaling and has an essential role in nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) activation and survival signaling. Increased expression of TRADD is sufficient to activate NF-κB. Recent studies have highlighted the importance of NF-κB activation as a key pathogenic mechanism in glioblastoma multiforme (GBM), the most common primary malignant brain tumor in adults.We examined the expression of TRADD by immunohistochemistry (IHC) and find that TRADD is commonly expressed at high levels in GBM and is detected in both cytoplasmic and nuclear distribution. Cytoplasmic IHC TRADD scoring is significantly associated with worse progression-free survival (PFS) both in univariate and multivariate analysis but is not associated with overall survival (n = 43 GBMs). PFS is a marker for responsiveness to treatment. We propose that TRADD-mediated NF-κB activation confers chemoresistance and thus a worse PFS in GBM. Consistent with the effect on PFS, silencing TRADD in glioma cells results in decreased NF-κB activity, decreased proliferation of cells, and increased sensitivity to temozolomide. TRADD expression is common in glioma-initiating cells. Importantly, silencing TRADD in GBM-initiating stem cell cultures results in decreased viability of stem cells, suggesting that TRADD may be required for maintenance of GBM stem cell populations. Thus, our study suggests that increased expression of cytoplasmic TRADD is both an important biomarker and a key driver of NF-κB activation in GBM and supports an oncogenic role for TRADD in GBM.

Abstract

Footnotes

This work was supported in part by National Institutes of Health (NIH) grant R01NS062080 to A.A.H. and by R01 CA139217 to D.A.B. S.B. is supported by grants from the NIH (R01 CA149461), National Aeronautics and Space Administration (NNX13AI13G), and the Cancer Prevention and Research Institute of Texas (RP100644).

This article refers to supplementary material, which is designated by Table W1 and is available online at www.neoplasia.com.

Footnotes

References

  • 1. Hsu H, Xiong J, Goeddel DVThe TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell. 1995;81:495–504.[PubMed][Google Scholar]
  • 2. Pobezinskaya YL, Liu ZThe role of TRADD in death receptor signaling. Cell Cycle. 2012;11:871–876.[Google Scholar]
  • 3. Aggarwal BBSignalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol. 2003;3:745–756.[PubMed][Google Scholar]
  • 4. Chen NJ, Chio II, Lin WJ, Duncan G, Chau H, Katz D, Huang HL, Pike KA, Hao Z, Su YW, et al Beyond tumor necrosis factor receptor: TRADD signaling in toll-like receptors. Proc Natl Acad Sci USA. 2008;105:12429–12434.[Google Scholar]
  • 5. Hsu H, Shu HB, Pan MG, Goeddel DVTRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell. 1996;84:299–308.[PubMed][Google Scholar]
  • 6. Micheau O, Tschopp JInduction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell. 2003;114:181–190.[PubMed][Google Scholar]
  • 7. Morgan M, Thorburn J, Pandolfi PP, Thorburn ANuclear and cytoplasmic shuttling of TRADD induces apoptosis via different mechanisms. J Cell Biol. 2002;157:975–984.[Google Scholar]
  • 8. Chio II, Sasaki M, Ghazarian D, Moreno J, Done S, Ueda T, Inoue S, Chang YL, Chen NJ, Mak TWTRADD contributes to tumour suppression by regulating ULF-dependent p19Arf ubiquitylation. Nat Cell Biol. 2012;14:625–633.[PubMed][Google Scholar]
  • 9. Wesemann DR, Qin H, Kokorina N, Benveniste ENTRADD interacts with STAT1-α and influences interferon-γ signaling. Nat Immunol. 2004;5:199–207.[PubMed][Google Scholar]
  • 10. Scheuerpflug CG, Lichter P, Debatin KM, Mincheva AAssignment of TRADD to human chromosome band 16q22 by in situ hybridization. Cytogenet Cell Genet. 2001;92:347–348.[PubMed][Google Scholar]
  • 11. Surawicz TS, McCarthy BJ, Kupelian V, Jukich PJ, Bruner JM, Davis FGDescriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990–1994. Neuro Oncol. 1999;1:14–25.[Google Scholar]
  • 12. Reardon DA, Wen PYTherapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Oncologist. 2006;11:152–164.[PubMed][Google Scholar]
  • 13. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, et al Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006;9:157–173.[PubMed][Google Scholar]
  • 14. Mischel PS, Cloughesy TF, Nelson SFDNA-microarray analysis of brain cancer: molecular classification for therapy. Nat Rev Neurosci. 2004;5:782–792.[PubMed][Google Scholar]
  • 15. Carro MS, Lim WK, Alvarez MJ, Bollo RJ, Zhao X, Snyder EY, Sulman EP, Anne SL, Doetsch F, Colman H, et al The transcriptional network for mesenchymal transformation of brain tumours. Nature. 2010;463:318–325.[Google Scholar]
  • 16. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, et al Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:98–110.[Google Scholar]
  • 17. Brennan C, Momota H, Hambardzumyan D, Ozawa T, Tandon A, Pedraza A, Holland EGlioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One. 2009;4:e7752.[Google Scholar]
  • 18. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, et al An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321:1807–1812.[Google Scholar]
  • 19. Cancer Genome Atlas Research Network, authorComprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455:1061–1068.[Google Scholar]
  • 20. Karin M, Cao Y, Greten FR, Li ZWNF-κB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002;2:301–310.[PubMed][Google Scholar]
  • 21. Pacifico F, Leonardi ANF-κB in solid tumors. Biochem Pharmacol. 2006;72:1142–1152.[PubMed][Google Scholar]
  • 22. Schauer IG, Zhang J, Xing Z, Guo X, Mercado-Uribe I, Sood AK, Huang P, Liu JInterleukin-1β promotes ovarian tumorigenesis through a p53/NF-κB-mediated inflammatory response in stromal fibroblasts. Neoplasia. 2013;15:409–420.[Google Scholar]
  • 23. Jain G, Voogdt C, Tobias A, Spindler KD, Moller P, Cronauer MV, Marienfeld RBIκB kinases modulate the activity of the androgen receptor in prostate carcinoma cell lines. Neoplasia. 2012;14:178–189.[Google Scholar]
  • 24. Thomasova D, Mulay SR, Bruns H, Anders HJp53-independent roles of MDM2 in NF-κB signaling: implications for cancer therapy, wound healing, and autoimmune diseases. Neoplasia. 2012;14:1097–1101.[Google Scholar]
  • 25. Park S, Hatanpaa KJ, Xie Y, Mickey BE, Madden CJ, Raisanen JM, Ramnarain DB, Xiao G, Saha D, Boothman DA, et al The receptor interacting protein 1 inhibits p53 induction through NF-κB activation and confers a worse prognosis in glioblastoma. Cancer Res. 2009;69:2809–2816.[Google Scholar]
  • 26. Bredel M, Scholtens DM, Yadav AK, Alvarez AA, Renfrow JJ, Chandler JP, Yu IL, Carro MS, Dai F, Tagge MJ, et al NFKBIA deletion in glioblastomas. N Engl J Med. 2011;364:627–637.[Google Scholar]
  • 27. Sun L, Carpenter GEpidermal growth factor activation of NF-κB is mediated through IκBα degradation and intracellular free calcium. Oncogene. 1998;16:2095–2102.[PubMed][Google Scholar]
  • 28. Habib AA, Chatterjee S, Park SK, Ratan RR, Lefebvre S, Vartanian T. The epidermal growth factor receptor engages receptor interacting protein and nuclear factor-κB (NF-κB)-inducing kinase to activate NF-κB. Identification of a novel receptor-tyrosine kinase signalosome. J Biol Chem. 2001;276:8865–8874.[PubMed]
  • 29. Biswas DK, Cruz AP, Gansberger E, Pardee ABEpidermal growth factor-induced nuclear factor κB activation: a major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc Natl Acad Sci USA. 2000;97:8542–8547.[Google Scholar]
  • 30. Hatanpaa KJ, Burma S, Zhao D, Habib AAEpidermal growth factor receptor (EGFR) in glioma: signal transduction, neuropathology, imaging and radioresistance. Neoplasia. 2010;12:675–684.[Google Scholar]
  • 31. Eyler CE, Rich JNLooking in the miR-ror: TGF-β-mediated activation of NF-κB in glioma. J Clin Invest. 2012;122:3473–3475.[Google Scholar]
  • 32. Hjelmeland AB, Wu Q, Wickman S, Eyler C, Heddleston J, Shi Q, Lathia JD, Macswords J, Lee J, McLendon RE, et al Targeting A20 decreases glioma stem cell survival and tumor growth. PLoS Biol. 2010;8:e1000319.[Google Scholar]
  • 33. Park S, Zhao D, Hatanpaa KJ, Mickey BE, Saha D, Boothman DA, Story MD, Wong ET, Burma S, Georgescu MM, et al RIP1 activates PI3K-Akt via a dual mechanism involving NF-κB-mediated inhibition of the mTOR-S6K-IRS1 negative feedback loop and down-regulation of PTEN. Cancer Res. 2009;69:4107–4111.[Google Scholar]
  • 34. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PBIdentification of human brain tumour initiating cells. Nature. 2004;432:396–401.[PubMed][Google Scholar]
  • 35. Collett D Modelling Survival Data in Medical Research. New York, NY: Chapman &amp; Hall/CRC; 2003. [PubMed][Google Scholar]
  • 36. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, Pastorino S, Purow BW, Christopher N, Zhang W, et al Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell. 2006;9:391–403.[PubMed][Google Scholar]
  • 37. Nogueira L, Ruiz-Ontanon P, Vazquez-Barquero A, Lafarga M, Berciano MT, Aldaz B, Grande L, Casafont I, Segura V, Robles EF, et al Blockade of the NFκB pathway drives differentiating glioblastoma-initiating cells into senescence both in vitro and in vivo. Oncogene. 2011;30:3537–3548.[PubMed][Google Scholar]
  • 38. Albanese C, Wu K, D'Amico M, Jarrett C, Joyce D, Hughes J, Hulit J, Sakamaki T, Fu M, Ben-Ze'ev A, et al IKKα regulates mitogenic signaling through transcriptional induction of cyclin D1 via Tcf. Mol Biol Cell. 2003;14:585–599.[Google Scholar]
  • 39. Cao Y, Bonizzi G, Seagroves TN, Greten FR, Johnson R, Schmidt EV, Karin MIKKα provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. Cell. 2001;107:763–775.[PubMed][Google Scholar]
  • 40. Chien Y, Kim S, Bumeister R, Loo YM, Kwon SW, Johnson CL, Balakireva MG, Romeo Y, Kopelovich L, Gale M, Jr, et al RalB GTPase-mediated activation of the IκB family kinase TBK1 couples innate immune signaling to tumor cell survival. Cell. 2006;127:157–170.[PubMed][Google Scholar]
  • 41. Huber MA, Azoitei N, Baumann B, Grunert S, Sommer A, Pehamberger H, Kraut N, Beug H, Wirth TNF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest. 2004;114:569–581.[Google Scholar]
  • 42. Perkins NDIntegrating cell-signalling pathways with NF-κB and IKK function. Nat Rev Mol Cell Biol. 2007;8:49–62.[PubMed][Google Scholar]
  • 43. Schneider G, Saur D, Siveke JT, Fritsch R, Greten FR, Schmid RMIKKα controls p52/RelB at the skp2 gene promoter to regulate G1- to S-phase progression. EMBO J. 2006;25:3801–3812.[Google Scholar]
  • 44. Aggarwal BBNuclear factor-κB: the enemy within. Cancer Cell. 2004;6:203–208.[PubMed][Google Scholar]
  • 45. Pahl HLActivators and target genes of Rel/NF-κB transcription factors. Oncogene. 1999;18:6853–6866.[PubMed][Google Scholar]
  • 46. Kirillova I, Chaisson M, Fausto NTumor necrosis factor induces DNA replication in hepatic cells through nuclear factor κB activation. Cell Growth Differ. 1999;10:819–828.[PubMed][Google Scholar]
  • 47. Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, Strauss MNF-κB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol. 1999;19:2690–2698.[Google Scholar]
  • 48. Kim DW, Gazourian L, Quadri SA, Romieu-Mourez R, Sherr DH, Sonenshein GEThe RelA NF-κB subunit and the aryl hydrocarbon receptor (AhR) cooperate to transactivate the c-myc promoter in mammary cells. Oncogene. 2000;19:5498–5506.[PubMed][Google Scholar]
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.